CAMBRIDGE, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the 2005 Credit Suisse First Boston Health Care Conference will be webcast live and may be accessed by visiting the Investors section of the Company’s website, http://www.millennium.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will include an overview of the Company, marketing plans for VELCADE(R) (bortezomib) Injection, R&D activities and other upcoming corporate events. The presentation will be delivered at 4:00 PM ET on Thursday, November 17, 2005 from the Arizona Biltmore Resort in Phoenix, Arizona.
The presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company’s website is http://www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com.
Contact:
Kyle Kuvalanka
(617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc.,+1-617-761-4734
Web site: http://www.millennium.com//
Company News On-Call: http://www.prnewswire.com/comp/114562.html/
